Increased circulating PD-1hiCXCR5- peripheral helper T cells are associated with disease severity of active ulcerative colitis patients

2021 ◽  
Vol 233 ◽  
pp. 2-10
Author(s):  
Yan Long ◽  
Changsheng Xia ◽  
Yuanyuan Sun ◽  
Yinting Ma ◽  
Lijuan Xu ◽  
...  
2003 ◽  
Vol 134 (1) ◽  
pp. 127-137 ◽  
Author(s):  
S. MELGAR ◽  
M. M.-W. YEUNG ◽  
A. BAS ◽  
G. FORSBERG ◽  
O. SUHR ◽  
...  

QJM ◽  
2020 ◽  
Vol 113 (Supplement_1) ◽  
Author(s):  
E H Nashaat ◽  
M M Mohamed ◽  
T M Aziz ◽  
M W Nakhla

Abstract Background ulcerative colitis (UC) is a chronic, idiopathic, inflammatory bowel disease that causes inflammation and ulcers in the innermost layers of the large intestine (colon) and rectum. Assessment of intestinal inflammation in UC is crucial and still remains a difficult challenge for the clinician. Although endoscopic modalities with biopsy sampling seem to be the most reliable method for estimating disease severity, they are invasive and costly. Apart from endoscopic interventions, disease severity can be assessed using both laboratory studies and non-invasive imaging tests. C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), white blood cells (WBCs), acid glycoprotein, platelet count and albumin are in common use but have only modest accuracy in reflecting UC disease activity. Therefore, adjunctive use of additional serum markers that will be more sensitive and specific for determination of disease activity and achieving diagnostic accuracy is strongly needed in daily clinical practice. Aim of the Work to investigate the diagnostic utility of beta 2 microglobulin (B2-M) levels and analyze this correlation with the activity of ulcerative colitis disease. Patients and Methods a case control study that was conducted at the Gastroenterology Clinic, Internal Medicine Department, Ain Shams University during the period of January to July 2018. 60 patients were recruited for the study. They were divided as follows; Group “A”: 40 patients newly diagnosed as ulcerative colitis based on colonoscopy and biopsy, subdivided as follows; 20 patients with active ulcerative colitis and 20 patients with inactive ulcerative colitis. Group “B”: 20 healthy individuals free from any systemic diseases serving as a control group. Results in this study, the serum levels of serum B2-microglobulins were highest in patients with active ulcerative colitis compared to those with inactive ulcerative colitis and the control groups. Also B2-microglobulins values become higher with higher number of presenting symptoms and endoscopic activity, which becomes higher in severe disease. Conclusion our results revealed that serum B2-microglobulin was simple and non-invasive marker that could be helpful for differentiating active UC from inactive disease. Moreover, it was more helpful when used together with serum laboratory inflammatory indices (ESR and CRP).


2010 ◽  
Vol 4 (3) ◽  
pp. 275-282 ◽  
Author(s):  
Chris D. Poole ◽  
Mark P. Connolly ◽  
Sandy Kildegaard Nielsen ◽  
Craig J. Currie ◽  
Philippe Marteau

2015 ◽  
Vol 10 (3) ◽  
pp. 346-353 ◽  
Author(s):  
Antonella D’Ambrosio ◽  
Andrea Cossu ◽  
Antonello Amendola ◽  
Alessandro Zandri ◽  
Alessia Butera ◽  
...  

2012 ◽  
Vol 142 (5) ◽  
pp. S-887
Author(s):  
Antonella D'Ambrosio ◽  
Andrea Cossu ◽  
Massimo Sanchez ◽  
Annamaria Pronio ◽  
Chiara Montesani ◽  
...  

2020 ◽  
Author(s):  
Dafeng Liu ◽  
Yong Wang ◽  
Lijuan Lan ◽  
Yaling Liu ◽  
Bennan Zhao ◽  
...  

Abstract Background The outbreak of coronavirus disease 2019 (COVID-19) is widespread throughout China and the world. Methods Demographic, clinical data of 95 confirmed cases with COVID-19 on admission at the Public and Health Clinic Centre of Chengdu from January 16 to March 16, 2020, were retrospectively collected and analyzed. Of them 76, 19 cases were enrolled in non-DM group (without DM), DM group (with DM), respectively; according to the disease severity 57, 19, 8, 11 cases were further divided into non-severe non-DM subgroup (light and common type and without DM), severe non-DM subgroup (severe and critical illness type and without DM), non-severe DM subgroup (light and common type and with DM), severe DM subgroup (severe and critical illness type and with DM), respectively. The severe rate and the prognosis was compared between two groups. The data of peripheral lymphocyte and subsets, age, glucose metabolism parameters were compared between four subgroups, and its relationship to the disease severity, the viral negative conversion time, and the prognosis were analyzed.Results In this COVID-19 cohort the proportion of DM was 20%. Patients with DM had significantly higher severe rate and worse prognosis than those without DM, the difference was significant (severe rate ,cured, unhealed and death in DM and non-DM groups:61.11%vs.25.00%,26.32%,68.42%;5.26%vs.71.05%,26.32%,2.68%,х2=2.940, 3.394,P=0.003,0.001,respectively),simultaneously the proportion of DM in severe cases was higher than that in non-severe cases, the obvious difference was found (36.67% vs.12.31%,х2=2.744,P=0.006).Severe cases with DM tended to have the lowest lymphocytes count levels and percentage values, as well as the lowest T cells count levels and percentage values, helper T cells count levels and percentage values, suppressor T cells count levels, B cells count levels and percentage values compared with those severe cases without DM and non-severe cases with or without DM. The important influencing factors were that age, DM, lymphocyte percentage values and helper T cells percentage values for the disease severity, lymphocyte percentage values and B cell percentage values for the viral negative conversion time, and age, the disease severity and the viral negative conversion time for the prognosis.Conclusions The COVID-19 severe cases with DM had the lowest lymphocytes count level and percentage value, especially T and B lymphocytes count levels and percentage value. Overall decreased lymphocytes subsets and DM maybe worsen prognosis by worsening the disease severity and prolonging the viral negative conversion time. Combination immunomodulatory therapy based on comprehensive treatment might improve prognosis of the COVID-19 severe cases with DM.


Sign in / Sign up

Export Citation Format

Share Document